Global /China /Healthcare /Drug Manufacturers - General /000411
chevron_leftBack

Zhejiang Int'l Group Co.,Ltd.

000411
SHE: 000411 Delayed
10.44CNY -0.5%
1.43 USD
As of 24 April 2025, Zhejiang Int'l Group Co.,Ltd. has a market cap of $746.99M USD, ranking #9677 globally and #2830 in China. It ranks #932 in the Healthcare sector, and #50 in the Drug Manufacturers - General industry.
Global Rank
9677
Country Rank
2830
Sector Rank
932
Industry Rank
50
Key Stats
Market Cap
$746.99MUSD
5.44B CNY
Enterprise Value
$1.23BUSD
8.94B CNY
Revenue (TTM)
$4.52BUSD
32.91B CNY
EBITDA (TTM)
$131.28MUSD
956.67M CNY
Net Income (TTM)
$65.61MUSD
478.13M CNY
EBITDA Margin
2.9%
Profit Margin
1.5%
PE Ratio
11.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Yang Wang open_in_new
Employees
2,924
Founded
1950
Website
intmedic.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.5% 2.2% -2.4% 0.5% 3.4% 2.2%
Upcoming Earnings
Earnings Date
Fri, Apr 25 Tomorrow

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
000411
浙江英特集团股份有限公司
ISIN: CNE0000008D9
Shares Out.:
517.886M1 Shares Float: 517.762M2
TV:
SA:
YF:
GF:
BA:
MS:
10.44 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Zhejiang Int'l Group Co.,Ltd.

Zhejiang Int'l Group Co.,Ltd. engages in the wholesale and retail of pharmaceuticals and medical devices. The company was founded in 1950 and is based in Hangzhou, China.

Similar Companies

Industry: Drug Manufacturers - General (China)
Name
Market Cap diff.
Jiangsu Hengrui Medicine Co., Ltd.
600276
$44.58B
324.86B CNY
6K%
Zhangzhou Pientzehuang Pharmaceutical., Ltd.
600436
$16.98B
123.71B CNY
2K%
CSPC Pharmaceutical Group Ltd.
1093
$9.1B
70.59B HKD
1K%
Sichuan Kelun Pharmaceutical Co., Ltd.
002422
$7.56B
55.12B CNY
913%
Yifan Pharmaceutical Co., Ltd.
002019
$1.89B
13.75B CNY
153%
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
Eli Lilly and Co.
LLY
$744.81B
100K%
Johnson & Johnson
JNJ
$374.44B
50K%
AbbVie Inc.
ABBV
$313.2B
42K%
Novo Nordisk A/S
NOVO-B
$276.68B
1.82T DKK
37K%
Roche Holding AG
RO
$250.88B
207.2B CHF
33K%